After investigating tens of potential methylation biomarkers in lung cancer samples (data not shown), we selected the CpG islands of the CDH1, RASSF1A, PRPH and DLC1 gene promoters, because they displayed aberrant methylation in more than 50% of lung cancer samples and no aberrant methylation in normal tissues. The gene discussed is PRPH; the disease is lung carcinoma.